Cystic Fibrosis (CF) Diagnostics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Test Type (Antenatal Testing, Carrier Testing, Sweat Tests, CFTR-Related Metabolic Syndrome (CRMS), Newborn screening, Prenatal Screening), By Product Type (Diagnostic Kits, Reagents, and Others), By End User (Hospitals and Diagnostic Centers) and Region Forecast 2019-2030

Cystic fibrosis (CF) diagnostics market size was valued at US$ 8.13 billion in 2023, growing at a CAGR of 18% from 2024-30. Cystic fibrosis (CF) is a chronic, genetic disease that causes persistent lung infections and limits the ability to breathe over time. Several mutations in the gene is responsible for Cystic fibrosis that encodes cystic fibrosis transmembrane conductance regulator (CFTR) protein. Patients with CF have inherited two copies of the defective CF gene one copy from each parent.

Both parents must have at least one copy of the defective gene. Currently, there are approximately 70,000 people who are suffering from cystic fibrosis worldwide, according to the Cystic Fibrosis Foundation (CFF). Some of the popular methods of diagnosis are antenatal testing, carrier testing, and other tests such as genetic tests and sweat tests According to Cystic Fibrosis Foundation, the incidence of these hereditary disorders is constantly growing. Nonprofit organizations are investing huge amounts of funds to find various therapeutics for CF and to support research & developmental activities. 

Key Developments

• In February 2018, Luminex's xTAG Cystic Fibrosis 71 Kit v2 was approved for sale with LICENSALE.COM in Brazil. In March 2017, Elucigene Diagnostics announced the official launch of a new CF-Italia kit (CF1ITB1). In April 2017, Elucigene Diagnostics partnered with Southern Cross Diagnostics in order to expand in Australia and New Zealand markets.